The cancer immunotherapy developer's latest round included pharmaceutical producers and co-founders Juno Therapeutics and WuXi AppTec.
JW Therapeutics, a China-based biopharmaceutical developer formed by biopharmaceutical companies Juno Therapeutics and WuXi AppTec, closed a $100m series B round on Tuesday featuring both among the investors.
The round was co-led by CPE, a subsidiary of state-owned holding company Citic, and financial services firm Mirae Asset, and included CR-CP Life Science Fund, a joint venture backed by conglomerate Charoen Pokphand Group and state-owned group China Resources.
Oriza Holdings, Loyal Valley Capital, Temasek, Sequoia Capital China and Arch Venture Partners…
